跳至主要内容
临床试验/JPRN-jRCTs031190149
JPRN-jRCTs031190149已完成未知

The relationship of AMPA receptor density in patients with autism spectrum disorder: A transversal PET study using [11C] K-2

Miyazaki Tomoyuki0 个研究点目标入组 30 人开始时间: 2019年12月2日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 < 60age old(—)
性别
All

入选标准

  • We will target cases that meet all the following conditions.
  • 1. Those who meets the criteria for Autism Spectrum Disorder (ASD) in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5).
  • 2. Men and women between 20 and 60 years old at the time of registration.
  • 3. Patients who have given written consent to participate in this study.
  • 4. Those who are judged to have sufficient consent judgment ability of the person in the evaluation by MacCAT.

排除标准

  • It will be excluded if any of the following conditions apply.
  • 1 During pregnancy, nursing or wishing to be pregnant(For premenopausal women,blood hCG is measured by blood sampling and confirmed to be less than 6 mIU/ml)
  • 2 Sensitive to alcohol
  • 3 Combination of serious neurologic diseases (neurodegenerative diseases, cases of cerebral hemorrhage and cerebral infarction which are not slight in the image before this study participation)
  • 4 History of epilepsy
  • 5 Take Perranpanel, Topiramate within 4 weeks before registration
  • 6 Substance-related disorders within 6 months (except for nicotine and caffeine)
  • 7 Dependent substances positive by urine screening (except those who are positive for the medicine being taken for treatment)
  • 8 Implantation of metal substances and pacemakers
  • 9 head, neck and body size not suitable for MRI scanner
  • 10 A tattoo larger than one point (including tattoo and art makeup)
  • 11 Advanced claustrophobic
  • 12 A remarkable variant of brain structure (including congenital and traumatic)
  • 13 At the time of registration, any of the following laboratory test value abnormalities
  • Serum creatinine 1.5 mg / dl or more
  • AST 150 IU / L or more
  • ALT 150 IU / L or more
  • 14 Participating in unapproved nuclear medicine clinical trials and clinical trials within 6 months prior to enrollment
  • 15 Participating in other trials or clinical trials within 12 weeks prior to enrollment (limited to those with invasiveness / intervention)
  • 16 Patients judged as inappropriate for study by the research investigator
  • 17 Patients under IQ70 in WAIS-3 or WAIS-4

研究者

发起方
Miyazaki Tomoyuki

相似试验